Results of the SELECT trial, which originally studied over 17,000 adults with heart disease and a body mass index (BMI) 27kg/m, comparing semaglutide to placebo, demonstrated that that those taking the drug for more than three years had a 20% lower risk of heart attack, stroke or death due to cardiovascular disease and lost an average of 9.4% of their body weight
After propensity score matching, the researchers identified 61,057 patients taking a GLP-1RA and an equal number taking other weight loss medications, including orlistat, phentermine-topiramate, bupropion-naltrexone or setmelanotide
Have the Drug Manufacturers of These Weight Loss and Diabetes Drugs Responded
Slightly different shade of pink between B12 batches, or a marginally different degree of yellow tint, can occur without indicating any quality problem
They are straightforward purchasing approaches that vendors openly support because higher volume means guaranteed revenue for them
More severe GI side effects were seen in oral administration, and injections were associated with irritation at sites of administration [1]
